---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-227977"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2024-09-27T23:59:59+00:00"
generated_at: "2026-05-31T01:10:51.345527+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma prices $12M public offering of stock and warrants, extends cash runway into Q4 2025

## Summary
- 10.6M shares of common stock and 2.9M common stock warrants offered at $0.50 per unit; pre-funded warrants for 12.4M shares at $0.499.
- Net proceeds estimated at $10.7M after underwriting discounts and expenses.
- Oppenheimer & Co. is sole book-running manager; closing expected September 30, 2024.
- Cash runway extended into fourth quarter of 2025, based on current plans.
- Warrants: pre-funded exercisable at $0.001, common stock warrants at $0.50, expire in five years.

## SEC filing metadata
- accession: 0001193125-24-227977
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2024-09-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000119312524227977/0001193125-24-227977-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000119312524227977/d856255d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-227977
- JSON: https://secwatch.observer/filing/0001193125-24-227977.json
- Plain text: https://secwatch.observer/filing/0001193125-24-227977.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.